Intismeran Autogene (V940)
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for Intismeran Autogene (V940), covering 2025-09-24 to 2026-04-22. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) [Phase 3]